Marion S. Helfand - Concepedia

Author

Marion S. Helfand

Louis Stokes Cleveland VA Medical Center

Also Known As

M HELFAND, M. S. Helfand, M.S. Helfand, Marion Helfand, Marion S. Helfand, Marion Skalweit Helfand, Marion S. Helfand

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Louis Stokes Cleveland VA Medical Center Case Western Reserve University University Hospitals of Cleveland Southern Methodist University University School

About

Marion S. Helfand is an author at Louis Stokes Cleveland VA Medical Center specializing in medicine, clinical microbiology, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	484
2	Health Sciences	8	8	367
3	Natural Sciences	2	2	46
4	Engineering	1	1	13
5	Allergy	1	1	38

Marion S. Helfand

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Identification of a New Allelic Variant of the<i>Acinetobacter baumannii</i>Cephalosporinase, ADC-7 β-Lactamase: Defining a Unique Family of Class C Enzymes Kristine M. Hujer, Nashaat S. Hamza, Andrea M. Hujer, Antimicrobial Agents and Chemotherapy	2005	145
β‐Lactam Antibiotics and Gastrointestinal Colonization with Vancomycin‐Resistant Enterococci Louis B. Rice, Rebecca Hutton‐Thomas, Viera Laktičová, The Journal of Infectious Diseases Antimicrobial SusceptibilityHealth SciencesAntimicrobial StewardshipAntibioticsMedicine	2004	82
High Resolution Crystal Structures of the trans-Enamine Intermediates Formed by Sulbactam and Clavulanic Acid and E166A SHV-1 β-Lactamase Pius S. Padayatti, Marion S. Helfand, Monica A. Totir, Journal of Biological Chemistry	2005	72
Clavulanic Acid Inactivation of SHV-1 and the Inhibitor-resistant S130G SHV-1 β-Lactamase Deley L. Sulton, Doritza Pagán-Rodríguez, Xiang Zhou, Journal of Biological Chemistry Antimicrobial ChemotherapyAntiviral DrugDrug ResistanceAntiviral Drug DevelopmentPenicillin-resistant Pathogens	2005	70
Tazobactam Forms a Stoichiometric <i>trans</i>-Enamine Intermediate in the E166A Variant of SHV-1 β-Lactamase: 1.63 Å Crystal Structure<sup>,</sup> Pius S. Padayatti, Marion S. Helfand, Monica A. Totir, Biochemistry	2004	69
Following the Reactions of Mechanism-Based Inhibitors with β-Lactamase by Raman Crystallography Marion S. Helfand, Monica A. Totir, Marianne P. Carey, Biochemistry	2003	67
Understanding Resistance to β-Lactams and β-Lactamase Inhibitors in the SHV β-Lactamase Marion S. Helfand, Christopher R. Bethel, Andrea M. Hujer, Journal of Biological Chemistry	2003	66
Mechanisms by Which Anaerobic Microbiota Inhibit the Establishment in Mice of Intestinal Colonization by Vancomycin‐Resistant<i>Enterococcus</i> Nicole J. Pultz, Usha Stiefel, Suja Subramanyan, The Journal of Infectious Diseases DysbiosisImmunologyMucus LayerDigestive TractDrug Resistance	2005	66
Rational Design of a β-Lactamase Inhibitor Achieved via Stabilization of the <i>trans</i>-Enamine Intermediate: 1.28 Å Crystal Structure of <i>wt</i> SHV-1 Complex with a Penam Sulfone Pius S. Padayatti, Anjaneyulu Sheri, Monica A. Totir, Journal of the American Chemical Society	2006	53
Tazobactam Inactivation of SHV-1 and the Inhibitor-resistant Ser130 → Gly SHV-1 β-Lactamase Doritza Pagán-Rodríguez, Xiang Zhou, Reiko Simmons, Journal of Biological Chemistry	2004	52

Page 1